Indian Pharma Market Posts 10.60% Growth in December 2025, Led by Torrent and Cipla
The Indian pharmaceutical market recorded 10.60% growth in December 2025, with major companies like Torrent Pharma (17.20%), Cipla (15.50%), and Sun Pharma (15.20%) leading the expansion. The anti-diabetic segment, valued at ₹22,280.00 crore, grew 9.40% on MAT basis, while Eli Lilly's Mounjaro dominated monthly brand rankings with ₹601.00 crore in MAT sales, reflecting the sector's strong momentum across therapeutic areas.
*this image is generated using AI for illustrative purposes only.
The Indian pharmaceutical market concluded December 2025 with strong momentum, posting total IPM value growth of 10.60% according to Pharmatrac data. The performance was driven by robust growth across major pharmaceutical companies, with several players achieving impressive double-digit expansion rates during the month.
Major Pharma Companies Drive Market Growth
Leading pharmaceutical companies demonstrated exceptional performance in December 2025, with growth rates significantly outpacing the overall market average:
| Company | Growth Rate |
|---|---|
| Torrent Pharma | 17.20% |
| Cipla | 15.50% |
| Sun Pharma | 15.20% |
| Lupin | 12.80% |
| Zydus | 12.70% |
| Dr Reddy's | 10.10% |
| Mankind Pharma | 8.40% |
Torrent Pharma emerged as the top performer with 17.20% growth, followed closely by Cipla and Sun Pharma, both exceeding 15.00% growth rates. The consistent double-digit performance across major players indicates broad-based strength in the pharmaceutical sector.
Anti-Diabetic Segment Shows Strong Momentum
The anti-diabetic segment continued its robust expansion, reaching a valuation of ₹22,280.00 crore with 9.40% growth on a MAT basis as of December 2025. This performance positions it among the fastest-growing large chronic therapy areas in the Indian pharmaceutical market, reflecting the increasing focus on diabetes and metabolic care solutions.
Mounjaro Dominates Monthly Brand Rankings
Eli Lilly's Mounjaro achieved the number one brand position in December 2025 based on monthly performance, demonstrating remarkable market penetration since its launch. The brand has maintained its leadership position as the top-selling drug by value every month since October 2025, despite premium pricing strategies. Mounjaro's MAT sales reached ₹601.00 crore as of December 2025, representing the fastest brand rise to monthly value leadership in recent market history.
Top-Performing Brands by MAT Sales
Several established and emerging brands demonstrated strong performance in December 2025:
| Brand | Company | MAT Sales | Therapeutic Area |
|---|---|---|---|
| Glycomet GP | USV | ₹871.00 crore | Anti-diabetic |
| Augmentin | GSK | ₹889.00 crore | Antibiotic |
| Foracort | Cipla | ₹828.00 crore | Respiratory |
| Pan | Alkem | ₹820.00 crore | Gastroenterology |
| Mixtard | Abbott | ₹796.00 crore | Anti-diabetic |
The performance data reveals a dynamic competitive landscape where both legacy brands and new-age therapies are achieving significant market success. The strong showing across diverse therapeutic areas indicates broad-based demand growth in the Indian pharmaceutical market, with diabetes care emerging as a particularly robust segment driving overall market expansion.
19
